norepinephrine (ne)

Tedatioxetine hydrobromide (Lu AA 24530 hydrobromide) is a serotonin-norepinephrine-dopamine reuptake inhibitor and an antagonist of 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptors, which can be used to treat depression and anxiety.

Clovoxamine (DU 23811) is a 5-hydroxytryptamine reuptake, serotonin and norepinephrine inhibitor with antidepressant and anticonvulsant activity.

Nolomirole HCl (CHF 1035) is a novel selective dopamine agonist with oral activity and inhibitory effects on norepinephrine release, which can be used to study mild chronic heart failure.

Losulazine is a peripheral sympathetic antihypertensive compound that can be taken orally. Losulazine causes relatively modest, transient depletion of dopamine and norepinephrine in brain regions protected by the blood-brain barrier.

Diosmin (Venosmine) is a bioflavonoid that strengthens vascular walls.

Desvenlafaxine (O-Desmethylvenlafaxine) is a cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a serotonin and noradrenaline reuptake inhibitor (SNRI) and is used as an antidepressive agent.

Desvenlafaxine succinate hydrate (WY 45233 Succinate) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI).

Centanafadine hydrochloride (EB-1020 hydrochloride) is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter, also inhibits serotonin transporter (IC50s: 6 nM, 38 nM, and 83 nM for human NE, DA, and serotonin transporter).

Atomoxetine (HSDB 7352) is a selective norepinephrine inhibitor that may cause an increase in blood pressure by increasing norepinephrine concentrations in peripheral sympathetic neurons .Atomoxetine is a highly selective antagonist of presynaptic norepinephrine transporters with little or no affinity for other norepinephrine receptors or other neurotransmitter transporters or receptors, but has little or no affinity for 5- hydroxytryptamine transporter. Atomoxetine selectively inhibits reuptake of norepinephrine and can be used to treat adolescents with ADHD and chronic tics.

Amitifadine hydrochloride (EB-1010 hydrochloride) is a triple reuptake inhibitor (TRI) or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).

Asenapine (Org 5222) is a 5-HT receptor, adrenergic receptor, dopamine receptor, and histamine receptor antagonist with antipsychotic effects that is used to treat schizophrenia and manic or mixed episodes associated with bipolar 1 disorder.721483-46-5

Reboxetine (Norebox) is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under trade names including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R, R)-(-)- and (S, S)-(+)-reboxetine.

Dasotraline hydrochloride (SEP-225289 hydrochloride) is a triple reuptake inhibitor that inhibits dopamine, norepinephrine, and serotonin transporters with IC50 values of 4, 6, and 11 nM, respectively.

WAY-260022 is an orally available and selective norepinephrine transporter protein inhibitor that displays inhibitory effects on serotonin and dopamine transporter proteins.

Tampramine is a selective norepinephrine reuptake inhibitor that shows a low affinity for adrenergic, histaminergic and muscarinic receptors. Tampramine is a candidate compound for the treatment of forced swimming test (FST) depression.

Atomoxetine hydrochloride (LY 139603) is the hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft. The effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels.

Citalopram hydrobromide (XU-62-320) , a selective serotonin reuptake inhibitor (SSRI), selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). Citalopram hydrobromide is the orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA).

Venlafaxine (Wy 45030), an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), is used to treat major generalised anxiety disorder (GAD), depressive disorder (MDD), panic disorder and social phobia.

Guanethidine monosulfate is an antihypertensive drug that reduces the release of catecholamines.

Dextromilnacipran (Levomilnacipran) is a selective serotonin and norepinephrine reuptake inhibitor.

Centanafadine is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter, also inhibits serotonin transporter (IC50s: 6 nM, 38 nM, and 83 nM for human NE, DA, and serotonin transporter).

4-Methylamphetamine hydrochloride is a 5-HT1A receptor agonist that induces a decrease in body temperature in rats by binding to the 5-HT1A receptor. Additionally, it increases the extracellular levels of neurotransmitters norepinephrine (NE), dopamine (DA), and serotonin (5-HT) by affecting their transporters. 4-Methylamphetamine hydrochloride is applicable in the study of neurological disorders.

5-Fluoro-α-methyltryptamine hydrochloride may increase intracellular 5-HT levels, subsequently enhancing the release of 5-HT. The EC50 values for 5-Fluoro-α-methyltryptamine hydrochloride are 37 nM for dopamine (DA), 14 nM for 5-hydroxytryptamine (5-HT), 78 nM for norepinephrine (NE), and 8.47 nM for the 5-HT2A receptor.

Levomilnacipran (F2696; (1R,2S)-milnacipran) is the enantiomer of milnacipran and acts as a selective serotonin and norepinephrine (5-HT/NE) reuptake inhibitor. It also serves as a human α-adrenergic receptor antagonist with an IC50 of 3.4 μM, as detailed in patent WO2013014263A1.